Dazodalibep (VIB4920/HZN4920) in Sjögren’s Subjects with an Unacceptable Symptom Burden: Safety and Efficacy from a Phase 2, Randomized, Double-Blind
Discussion in ''Conditions related to ME/CFS' news and research' started by EndME, Nov 19, 2023.
Tags: